INTRODUCTION
PROLIFERATION, MALIGNANCIES, METASTATIC CHOLANGIOCARCINOMA
Fibroblast growth factor receptor (FGFR) signaling regulates essential cellular functions including proliferation and survival, and is mediated by crosstalk between 4 highly conserved tyrosine kinase receptors (FGFR1, FGFR2, FGFR3, and FGFR4) and 22 fibroblast growth factor (FGF) ligands.Genetic alterations in Pemigatinib (INCB054828) is a potent and selective inhibitor of Based on promising safety and efficacy results from FIGHT‐101, the pivotal phase 2 FIGHT‐202 study (NCT02924376) was initiated. In FIGHT‐202, pemigatinib demonstrated improved and sustained responses in patients with advanced or metastatic cholangiocarcinoma with The clinical benefit observed in patients in FIGHT‐101 prompted the FIGHT‐102 study (NCT03235570), an open‐label, phase 1 study of pemigatinib in Japanese patients with advanced solid malignancies. Here, we report the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of pemigatinib in FIGHT‐102.